Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix

Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
PharmiWeb

Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products ...
Thoroughbred Daily News

Two Veterinarians Suspended By HISA After Track-Office Searches At Laurel And Delaware Allegedly Turn Up Banned Substances

Two veterinarians suspended by HISA after track-office searches at Laurel and Delaware allegedly turn up banned substances ...

Food prices will rise in 2026 – and suppliers need them to

The 2026 pricing round will filter into retail prices across late January and February, taking inflation back up to 5%, says, ...

Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew ...

Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties

Ad hoc announcement pursuant to Art. 53 LRExclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD ...

Santhera Pharmaceuticals Holding AG: Santhera Receives Swissmedic Approval of AGAMREE (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 - Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissme ...
Le Lézard

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity ...

Johnson & Johnson today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 ...

Santhera Pharmaceuticals Holding AG: Santhera Licenses AGAMREE (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 ...

Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share ...
Pharmabiz

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

AstraZeneca’s DAHLIA Lupus Study: Real‑World Data Could Strengthen Anifrolumab’s Long‑Term Investment Case

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., ...